Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

This research is testing a new medicine, EPX-100 (also known as clemizole hydrochloride), for people with Dravet syndrome. Dravet syndrome is a type of epilepsy that causes severe seizures. The study wants to find out if EPX-100 can reduce seizures and if it's safe for children and adults who are already taking other seizure medications. Some participants will receive the active medicine, while others will receive a placebo (dummy medicine), so we can compare the effects. Researchers are carefully monitoring participants to understand how well the new medicine works and if there are any side effects. This is a "Phase 3" study, which means it's one of the final steps before a medicine might be approved for wider use.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Epygenix
Einschreibeziel
150
Starten
15 Sep 2020
Geschätzte Fertigstellung
01 May 2029

Worum geht es in dieser Studie?

Dravet syndrome is a challenging type of epilepsy that often begins in infancy and continues throughout life. It causes frequent and prolonged seizures, which can be difficult to control, even with many medications. Because of this, doctors and researchers are always looking for new and better ways to help people living with Dravet syndrome.

This study is focusing on a medicine called EPX-100, or clemizole hydrochloride. The main goal is to see if adding EPX-100 to a person's current seizure medications (this is called "adjunctive therapy") can help reduce the number of seizures they experience. We also want to make sure it's safe to use. By comparing EPX-100 to a placebo, which looks exactly like the real medicine but contains no active drug, researchers can get a clear picture of how effective EPX-100 truly is.

This is a large, worldwide study taking place in many different centres. It's a "Phase 3" study, meaning it's one of the final stages of testing before a new medicine might be considered for approval. This phase involves a larger group of people to confirm the findings from earlier studies and gather more information about safety and effectiveness over a longer period.

Wichtige Erkenntnisse

  • Tests a new medicine (EPX-100) for Dravet syndrome alongside current treatments.
  • Aims to see if EPX-100 can reduce seizures and is safe.
  • Involves children and adults aged 2 years and older.
  • Compares EPX-100 to a dummy medicine (placebo) in a fair way.
  • Participation includes observation, a 16-week main study, and an optional longer-term period.
  • You can stop participating at any time if you change your mind.

Wer könnte berechtigt sein?

To join this study, participants must be at least 2 years old. A parent or legal guardian must agree for children to take part, and adults must agree themselves. Everyone involved needs to have a clear diagnosis of Dravet syndrome and still be experiencing seizures, even if they're taking other medicines.

There are also some specific medical requirements for those with Dravet syndrome. These include having had seizures before 18 months of age, showing normal development at the beginning, and a specific genetic change (mutation) in something called the SCN1A gene. Your doctor will be able to check all these details.

However, some things would mean you can't join the study. If you've had an allergic reaction to clemizole HCl before, or if you're taking part in another drug study, you wouldn't be able to participate. Also, certain other health conditions, specific medications (like lorcaserin or fenfluramine), or recent brain surgery for epilepsy would prevent you from joining.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you, or the person you care for, 2 years old or older?
  2. Do you have a clear diagnosis of Dravet syndrome with ongoing seizures?
  3. Did seizures start before 18 months of age with normal development at that time?
  4. Has a specific genetic change (SCN1A gene mutation) been identified?
  5. Are you willing to attend regular study appointments?
  6. Have you *not* had a known allergic reaction to clemizole HCl in the past?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, the study will involve several stages. First, there will be an "Observational Period" lasting about 4 weeks. During this time, the study team will get to know your usual seizure patterns without making any changes to your medication.

After that, you'll enter the "Double-Blind Period" for 16 weeks. In this part, you'll be given either the study medicine (EPX-100) or a placebo, but neither you, your doctor, nor the study team will know which you are receiving. This helps make the study fair and accurate. You'll continue to take your regular seizure medications as well.

After the 16 weeks, there's an "Open-Label Extension (OLE) Period." In this stage, everyone who completes the initial period will have the chance to receive the actual study medicine (EPX-100) if they wish, and everyone will know what they are taking. Throughout all periods, you'll have regular visits with the study team for check-ups, to monitor your seizures, and to make sure you're feeling well. The total length of your participation will depend on how long you stay in the open-label extension.

Potenzielle Risiken und Vorteile

Taking part in any medical study has both potential benefits and risks. You might benefit if EPX-100 helps reduce your seizures. You would also be contributing important information that could help others with Dravet syndrome in the future. However, there's a chance you might experience side effects from the study medication, or you might receive the placebo and therefore not see any improvement in your condition. You are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (86)

  • Universität von Alabama in Birmingham
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten· Rekrutierung
  • Arkansas Children's Hospital
    Verifizierte Postleitzahl
    Little Rock, Vereinigte Staaten· Rekrutierung
  • Children's Hospital of Los Angeles
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Beendet
  • Universität von Kalifornien Irvine
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten· Rekrutierung
  • UCSF Medical Center
    Verifizierte Postleitzahl
    San Francisco, Vereinigte Staaten· Beendet
  • Yale School of Medicine - Yale-New Haven Hospital
    Verifizierte Postleitzahl
    New Haven, Vereinigte Staaten· Rekrutierung
  • The Nemours Foundation
    Verifizierte Postleitzahl
    Wilmington, Vereinigte Staaten· Beendet
  • Rare Disease Research FL
    Verifizierte Postleitzahl
    Kissimmee, United States· Beendet
  • Pediatric Neurology and Epilepsy Specialists
    Verifizierte Postleitzahl
    Winter Park, United States· Rekrutierung
  • Clinical Integrative Research Center of Atlanta (CIRCA)
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten· Zurückgezogen
  • Ann & Robert H. Lurie Kinderkrankenhaus von Chicago
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten· Beendet
  • Norton Children's Research Institute
    Verifizierte Postleitzahl
    Louisville, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What is Dravet syndrome?

Dravet syndrome is a severe type of epilepsy that typically starts in babies and causes frequent, long-lasting seizures that can be hard to control.

Was bedeutet 'placebo-kontrolliert'?

It means some people will get the actual medicine, and others will get a 'dummy' pill with no medicine in it. This helps researchers fairly compare the new medicine's effects.

Was ist eine 'Phase 3'-Studie?

Phase 3 is typically the final stage of testing a new medicine before it can be considered for approval. It involves more people to confirm its safety and effectiveness.

Can I continue my other seizure medicines?

Yes, this study is looking at EPX-100 as an 'add-on' treatment, meaning you will continue taking your existing seizure medications.

Werde ich wissen, ob ich das echte Medikament oder das Placebo erhalte?

During the main part of the study, neither you nor your doctor will know. This is called 'double-blind.' Later, in the 'open-label' part, everyone knows they are taking the active medicine.

Wie Sie mehr erfahren können

Krystle Rapchak

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study of EPX-100 (Clemizole Hydrochloride) in Participants… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.